Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD51 | Q06609 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30423878 | 1.00 | RAD51 (0.32) | RAD51PDE4BPDE4DHCRTR1HCRTR2 | |
| SCHEMBL24253533 | 0.82 | LMNA (0.35) | RAD51HCRTR1HCRTR2CYP11B2KCNH2 | |
| SCHEMBL30424161 | 0.82 | LMNA (0.35) | RAD51HCRTR1HCRTR2CYP11B2KCNH2 | |
| SCHEMBL30424392 | 0.80 | SCD (0.35) | RAD51PDE4BHCRTR1HCRTR2CYP11B2 | |
| SCHEMBL24253822 | 0.80 | SCD (0.35) | RAD51PDE4BHCRTR1HCRTR2CYP11B2 | |
| SCHEMBL24253729 | 0.76 | HCRTR1 (0.49) | RAD51HCRTR1HCRTR2KCNH2LTC4S | |
| SCHEMBL30423954 | 0.76 | HCRTR1 (0.49) | RAD51HCRTR1HCRTR2KCNH2LTC4S | |
| SCHEMBL24253726 | 0.75 | DPP4 (0.36) | RAD51PDE4BHCRTR1HCRTR2CYP11B2 | |
| SCHEMBL24253830 | 0.75 | AKT1S1 (0.36) | RAD51PDE4BHCRTR1HCRTR2CYP11B2 | |
| SCHEMBL30423907 | 0.75 | AKT1S1 (0.36) | RAD51PDE4BHCRTR1HCRTR2CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2023-07-25 | — | — | US | disclosed |
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2023-07-25 | — | — | US | disclosed |
| US-20220048909-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | REN, NR3C2, PKD1 | RAD51 3303/4885PDE4B 235/4885PDE4D 184/4885 |
| US-20220048909-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | REN, NR3C2, PKD1 | RAD51 3303/4885PDE4B 235/4885PDE4D 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.